After patient hospitalized, Peninsula drug developer stops 2nd chronic hepatitis B program this year

The stock of the 93-employee company, which was over $34 a share in the past year, is trading below $3.

Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2022 Category: American Health Authors: Ron Leuty Source Type: news